• 1.昆明醫(yī)學院第二附屬醫(yī)院急診科(昆明650101);;
  • 2.四川大學華西醫(yī)院胃腸外科中心(成都 610041);

目的  探討人生長激素（hGH）對化療大鼠機體狀態(tài)和造血功能的影響。方法  實驗選用健康成年SD大鼠136只，體重（200±50） g，標準喂養(yǎng)，采用隨機數(shù)字表法隨機分為5組： 正常對照組（空白組，n=8）、 生理鹽水對照組（NS組，n=32）、生長激素組（hGH組，n=32）、 化療組（CT組，n=32）及CT+hGH組（n=32）。 分別于實驗前及給藥后第7、14、21及28天稱量大鼠體重，采用骨髓涂片、病理切片及免疫組化法（增殖細胞核抗原檢測）檢測大鼠骨髓造血功能。結果  給藥后第7天CT+hGH組大鼠體重下降程度較CT組明顯減輕（P＜0.05）； CT組和CT+hGH組骨髓增生極度低下或明顯減低（P＜0.05）。 第14天CT+hGH組大鼠體重已為正增長，而CT組仍表現(xiàn)為體重丟失； CT+hGH組骨髓增生極度活躍，骨髓有核細胞總數(shù)較CT組明顯增加（P＜0.05）。 第7、14及21天CT組增殖細胞核抗原陽性細胞數(shù)均明顯低于hGH組和CT+hGH組（P＜0.05）。 給藥后第7天hGH組大鼠體重較空白組明顯增加（P＜0.05），其他不同時間點空白組、NS組與hGH組各指標檢測結果差異均無統(tǒng)計學意義（P gt;0.05）。結論  hGH能減少化療大鼠的體重丟失，對化療大鼠的骨髓抑制有一定的保護作用。

引用本文： 張毅,陳嘉勇,梁道明,袁勇,周東,伍曉汀. 生長激素對化療大鼠機體狀態(tài)和骨髓功能的影響. 中國普外基礎與臨床雜志, 2009, 16(12): 958-963. doi: 復制

1. Fahlke J, Ridwelski K, Schmidt C, et al. A multicentre phase Ⅱ study of docetaxel plus cisplatin for the treatment of advanced gastric cancer [J]. Chemotherapy, 2007; 53(6): 454-460.
2. Hofmann MA, Gabriel V, Milling A, et al. High-dose platinum combination therapy in pretreated patients with disseminated melanoma [J]. Chemotherapy, 2007; 53(6): 422-428.
3. Shimonov M, Hayat H, Chaitchik S, et al. Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver [J]. Chemotherapy, 2005; 51（2-3）: 111-115.
4. Bozzeti F, Gavazzi C, Mariani L, et al. Artificicial nutrition in cancer patients: which route, what composition [J]. World J Sury, 1999; 23(6): 577-583.
5. Vara-Thorbeck R, Guerrero JA, Ruiz-Requena E, et al. Can the use of growth hormone reduced the postoperative fatigue syndrome? [J]. World J Surg, 1996; 20(1): 81-87.
6. 楊澄宇, 李偉明, 駱曦圖. 應用重組人生長激素改善高齡病人術后疲勞綜合征的臨床研究 [J]. 腸外與腸內(nèi)營養(yǎng)， 2003； 10(3): 160-162.
7. 祁曉平, 黎介壽, 陳徹. 人生長激素對人結腸癌細胞LS-174-T增殖周期的影響 [J]. 腸內(nèi)與腸外營養(yǎng), 2001； 8(1): 8-10.
8. Tacke J, Bolder U, Herrmann A, et al. Long-term risk of gastrointestinal tumor recurrence after postoperative treatment with recombinant human growth hormone [J]. JPEN J Parenter Enteral Nutr， 2000; 24(3): 140-144.
9. Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study [J]. Lancet, 2002; 360(9329): 273-277.
10. Fiebig HH, Dengler W, Hendriks HR. No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone [J]. Anticancer Drugs, 2000; 11(8): 659-664.
11. 陳嘉勇, 張捷, 譚晶, 等. 胃結腸癌患者術后生長激素應用的價值評估 [J]. 中國普外基礎與臨床雜志, 1999; 6(6): 365-367.
12. 陳嘉勇, 甘平, 梁道明, 等. 重組人生長激素在體外對人直腸癌細胞株HR8348增殖的影響 [J]. 中國普外基礎與臨床雜志, 2003; 10(4): 362-365.
13. 陳嘉勇, 梁道明, 甘平, 等. 重組人生長激素對胃癌細胞生長的影響 [J]. 中華普通外科雜志, 2004; 19(12): 741-743.
14. 陳嘉勇, 梁道明, 甘平, 等. 人生長激素在體外對人胃癌細胞的作用 [J]. 中華實驗外科雜志, 2004; 21(5): 521-523.
15. Ng B, Wolf RF, Weksler B, et al. Growth hormone administration preserves lean body mass in sarcoma-bearing rats treated with doxorubicin [J]. Cancer Res, 1993; 53(22): 5483-5486.
16. Sirohi B, Powles R, Morgan G, et al. Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study [J]. Bone Marrow Transplant， 2007; 39(2): 115-120.
17. Murphy WJ, Tsarfaty G, Longo DL. Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine [J]. Blood, 1992; 80(6): 1443-1447.
18. Carlo-Stella C, Di Nicola M, Milani R， et al. Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone [J]. Exp Hematol， 2004; 32(2): 171-178.
19. Carlo-Stella C, Di Nicola M, Milani R, et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers [J]. Blood， 2004; 103(9): 3287-3295.
20. Golde DW, Bersch N, Li CH. Growth hormone: Species-specific stimulation of erythropoiesis in vitro [J]. Science， 1977; 196（4294）: 1112-1113.
21. Merchav S, Tatarsky I, Hochberg Z. Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor Ⅰ/somatomedin C and human growth hormone [J]. J Clin Invest， 1988; 81（3）: 791-797.
22. Tian ZG, Woody MA. Sun R, et al. Recombinant human growth hormone promotes hematopoietic reconstitution after syngeneic bone marrow transplantation in mice [J]. Stem Cells, 1998； 16(3): 193-199.
23. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actings [J]. Endocr Rev, 1995； 16(1): 30-34.
24. Tsarfaty G, Longo DL, Murphy WJ. Human insulin-like gr-owth factor Ⅰ exerts hematopoietic growth-promoting effects after in vivo administration [J]. Exp Hematol， 1994； 22（13）: 1273-1277.
25. Conzemius MG, Graham JC, Haynes JS, et al. Effects of treatment with growth hormone and somatostatin on efficacy of diammine [1, 1-cyclobutane dicarboxylato (2-)-0,0’]-(SP-4-2) in athymic rats with osteosarcoma [J]. Am J Vet Res, 2000； 61(6): 646-650.
  1. 1. Fahlke J, Ridwelski K, Schmidt C, et al. A multicentre phase Ⅱ study of docetaxel plus cisplatin for the treatment of advanced gastric cancer [J]. Chemotherapy, 2007; 53(6): 454-460.
  2. 2. Hofmann MA, Gabriel V, Milling A, et al. High-dose platinum combination therapy in pretreated patients with disseminated melanoma [J]. Chemotherapy, 2007; 53(6): 422-428.
  3. 3. Shimonov M, Hayat H, Chaitchik S, et al. Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver [J]. Chemotherapy, 2005; 51（2-3）: 111-115.
  4. 4. Bozzeti F, Gavazzi C, Mariani L, et al. Artificicial nutrition in cancer patients: which route, what composition [J]. World J Sury, 1999; 23(6): 577-583.
  5. 5. Vara-Thorbeck R, Guerrero JA, Ruiz-Requena E, et al. Can the use of growth hormone reduced the postoperative fatigue syndrome? [J]. World J Surg, 1996; 20(1): 81-87.
  6. 6. 楊澄宇, 李偉明, 駱曦圖. 應用重組人生長激素改善高齡病人術后疲勞綜合征的臨床研究 [J]. 腸外與腸內(nèi)營養(yǎng)， 2003； 10(3): 160-162.
  7. 7. 祁曉平, 黎介壽, 陳徹. 人生長激素對人結腸癌細胞LS-174-T增殖周期的影響 [J]. 腸內(nèi)與腸外營養(yǎng), 2001； 8(1): 8-10.
  8. 8. Tacke J, Bolder U, Herrmann A, et al. Long-term risk of gastrointestinal tumor recurrence after postoperative treatment with recombinant human growth hormone [J]. JPEN J Parenter Enteral Nutr， 2000; 24(3): 140-144.
  9. 9. Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study [J]. Lancet, 2002; 360(9329): 273-277.
  10. 10. Fiebig HH, Dengler W, Hendriks HR. No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone [J]. Anticancer Drugs, 2000; 11(8): 659-664.
  11. 11. 陳嘉勇, 張捷, 譚晶, 等. 胃結腸癌患者術后生長激素應用的價值評估 [J]. 中國普外基礎與臨床雜志, 1999; 6(6): 365-367.
  12. 12. 陳嘉勇, 甘平, 梁道明, 等. 重組人生長激素在體外對人直腸癌細胞株HR8348增殖的影響 [J]. 中國普外基礎與臨床雜志, 2003; 10(4): 362-365.
  13. 13. 陳嘉勇, 梁道明, 甘平, 等. 重組人生長激素對胃癌細胞生長的影響 [J]. 中華普通外科雜志, 2004; 19(12): 741-743.
  14. 14. 陳嘉勇, 梁道明, 甘平, 等. 人生長激素在體外對人胃癌細胞的作用 [J]. 中華實驗外科雜志, 2004; 21(5): 521-523.
  15. 15. Ng B, Wolf RF, Weksler B, et al. Growth hormone administration preserves lean body mass in sarcoma-bearing rats treated with doxorubicin [J]. Cancer Res, 1993; 53(22): 5483-5486.
  16. 16. Sirohi B, Powles R, Morgan G, et al. Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study [J]. Bone Marrow Transplant， 2007; 39(2): 115-120.
  17. 17. Murphy WJ, Tsarfaty G, Longo DL. Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine [J]. Blood, 1992; 80(6): 1443-1447.
  18. 18. Carlo-Stella C, Di Nicola M, Milani R， et al. Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone [J]. Exp Hematol， 2004; 32(2): 171-178.
  19. 19. Carlo-Stella C, Di Nicola M, Milani R, et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers [J]. Blood， 2004; 103(9): 3287-3295.
  20. 20. Golde DW, Bersch N, Li CH. Growth hormone: Species-specific stimulation of erythropoiesis in vitro [J]. Science， 1977; 196（4294）: 1112-1113.
  21. 21. Merchav S, Tatarsky I, Hochberg Z. Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor Ⅰ/somatomedin C and human growth hormone [J]. J Clin Invest， 1988; 81（3）: 791-797.
  22. 22. Tian ZG, Woody MA. Sun R, et al. Recombinant human growth hormone promotes hematopoietic reconstitution after syngeneic bone marrow transplantation in mice [J]. Stem Cells, 1998； 16(3): 193-199.
  23. 23. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actings [J]. Endocr Rev, 1995； 16(1): 30-34.
  24. 24. Tsarfaty G, Longo DL, Murphy WJ. Human insulin-like gr-owth factor Ⅰ exerts hematopoietic growth-promoting effects after in vivo administration [J]. Exp Hematol， 1994； 22（13）: 1273-1277.
  25. 25. Conzemius MG, Graham JC, Haynes JS, et al. Effects of treatment with growth hormone and somatostatin on efficacy of diammine [1, 1-cyclobutane dicarboxylato (2-)-0,0’]-(SP-4-2) in athymic rats with osteosarcoma [J]. Am J Vet Res, 2000； 61(6): 646-650.